Gilead Sciences

GILD Health Care Market cap $182B as of Sep 14, 2026 16:00 ET S&P 500

Q1 FY26 Jan 1 – Mar 31, 2026 reported May 7, 2026

Revenue$6.96B +4% year over year

Gross profit$5.52B 79% margin

Operating profit$2.59B 37% margin

Net profit$2.02B 29% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	6.96	100%	+4%
Biktarvy	3.36	48%	+7%
Other revenue	1.27	18%
Oncology product	0.81	12%
Trodelvy	0.40	6%	+37%
Yescarta	0.33	5%	−14%
Sofosbuvir velpatasvir	0.28	4%
Genvoya	0.26	4%	−27%
Vemlidy	0.24	3%
Cost of revenue	−1.45	21%
Gross profit	5.52	79% margin	+2pp
SG&A	−1.45	21%	+2pp
Other	−1.48	21%
Operating profit	2.59	37% margin	+4pp
Tax	−0.57
Net profit	2.02	29% margin	+9pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	7.9	100%	+5%
Cost of revenue	−1.6	20%
Gross profit	6.3	80% margin	+0pp
SG&A	−1.8	22%	−3pp
Other	−2.5	32%	+0pp
Operating profit	2.0	25% margin	−7pp
Tax benefit and other	0.2
Net profit	2.2	28% margin	+4pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	7.77	100%	+3%
Biktarvy	3.69	47%
Other revenue	1.41	18%
Total oncology	0.79	10%
Total cell therapy	0.43	6%
Royalty, contract & other	0.42	5%
Genvoya	0.38	5%
Yescarta	0.35	5%
Sofosbuvir/Velpatasvir	0.31	4%
Cost of revenue	−1.57	20%
Gross profit	6.20	80% margin	+1pp
SG&A	−1.36	17%	−2pp
Other	−1.52	20%	+0pp
Operating profit	3.33	43% margin	+31pp
Other income, net	0.31
Tax	−0.59
Net profit	3.05	39% margin	+23pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	7.08	100%	+2%
Biktarvy	3.53	50%	+9%
Other revenue	1.13	16%
Descovy	0.65	9%	+35%
Yescarta	0.39	6%	−5%
Genvoya	0.38	5%	−14%
Trodelvy	0.36	5%	+14%
Liver disease products	0.34	5%	−28%
Odefsey	0.30	4%	−5%
Cost of revenue	−1.50	21%
Gross profit	5.58	79% margin	+1pp
SG&A	−1.37	19%	−1pp
Other	−1.74	25%	+0pp
Operating profit	2.47	35% margin	−3pp
Interest & other costs	−0.05
Tax	−0.47
Net profit	1.96	28% margin	+4pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	6.67	100%	+0%
Biktarvy	3.15	47%	+7%
Other revenue	1.24	19%
Descovy	0.59	9%	+38%
Yescarta	0.39	6%	+2%
Genvoya	0.36	5%	−10%
Liver disease products	0.35	5%
Veklury	0.30	5%
Trodelvy	0.29	4%	−5%
Cost of revenue	−1.54	23%
Gross profit	5.13	77% margin	+0pp
SG&A	−1.26	19%	−2pp
Other	−1.63	24%	+0pp
Operating profit	2.24	34% margin	+98pp
Interest & other costs	−0.59
Tax	−0.33
Net profit	1.32	20% margin	+82pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 7, 2026 Operating margin 37% Net profit $2.02B	Jan 1 – Mar 31, 2026	May 7, 2026	$7.0B	+4%	37%	$2.02B	29%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 24, 2026 Operating margin 25% Net profit $2.18B	Oct 1 – Dec 31, 2025	Feb 24, 2026	$7.9B	+5%	25%	$2.18B	28%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 7, 2025 Operating margin 43% Net profit $3.05B	Jul 1 – Sep 30, 2025	Nov 7, 2025	$7.8B	+3%	43%	$3.05B	39%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 7, 2025 Operating margin 35% Net profit $1.96B	Apr 1 – Jun 30, 2025	Aug 7, 2025	$7.1B	+2%	35%	$1.96B	28%
Q1 FY25 Jan 1 – Mar 31, 2025 reported May 7, 2025 Operating margin 34% Net profit $1.32B	Jan 1 – Mar 31, 2025	May 7, 2025	$6.7B	+0%	34%	$1.32B	20%